Home - Invivoscribe

Cat #: 40880008

This DNA control is adjusted to a final concentration of 15 µg/mL in 1/10 TE (1mM Tris-HCl (pH 8.0), 0.1 mM EDTA). This diluent provides sufficient b...

View Product

Cat #: 40880118

LymphoQuant^® B-cell Internal Control

LymphoQuant B-cell Internal Controls may be spiked into specimens to estimate the respective number of IGH clonotype equivalents present. Addition o...

View Product

Cat #: 40880128

LymphoQuant^® T-Cell Internal Control

The T-cell LymphoQuant Internal Control and T-cell LymphoTrack Low Positive Control are utilized in controlled MRD studies of TRG and TRB gene rearran...

View Product

Cat #: 71210007

LymphoTrack^® IGH FR1 Assay – S5/PGM™

This LymphoTrack IGH FR1 Assay – S5/PGM represents a significant improvement over existing clonality assays using fragment analysis as it efficient...

View Product

Cat #: 71210009

LymphoTrack^® IGH FR1 Assay Kit A – MiSeq^®

This LymphoTrack IGH Assay – MiSeq represents a significant improvement over existing clonality assays using fragment size analysis as it efficientl...

View Product

Cat #: 71210039

LymphoTrack^® IGH FR1 Assay Panel – MiSeq^®

This LymphoTrack IGH Assay – MiSeq represents a significant improvement over existing clonality assays using fragment size analysis as it efficientl...

View Product

Cat #: 71210149

LymphoTrack^® IGH FR1 Assay Panel B – MiSeq®

This LymphoTrack IGH Assay – MiSeq represents a significant improvement over existing clonality assays using fragment size analysis as it efficientl...

View Product

Cat #: 71210057

LymphoTrack^® IGH FR1/2/3 Assay – S5/PGM™

The LymphoTrack IGH FR1/2/3 Assay for the Ion S5 and PGM represents a significant improvement over existing clonality assays using fragment analysis...

View Product

Cat #: 71210129

LymphoTrack^® IGH FR1/2/3 Assay Kit A – MiSeq^®

The LymphoTrack IGH FR1/2/3 Assay for MiSeq represent a significant improvement over existing clonality assays using fragment analysis as they efficie...

View Product

Cat #: 71210139

LymphoTrack^® IGH FR1/2/3 Assay Panel – MiSeq^®

The LymphoTrack IGH FR1/2/3 Assay for MiSeq represent a significant improvement over existing clonality assays using fragment analysis as they efficie...

View Product

Cat #: 71210037

LymphoTrack^® IGH FR2 Assay – S5/PGM™

The LymphoTrack IGH FR2 Assay for the Ion PGM represents a significant improvement over existing clonality assays using fragment analysis as they ef...

View Product

Cat #: 71210089

LymphoTrack^® IGH FR2 Assay Kit A – MiSeq^®

This LymphoTrack IGH Assay – MiSeq represents a significant improvement over existing clonality assays using fragment size analysis as it efficientl...

View Product

Cat #: 71210099

LymphoTrack^® IGH FR2 Assay Panel – MiSeq^®

This LymphoTrack IGH Assay – MiSeq represents a significant improvement over existing clonality assays using fragment size analysis as it efficientl...

View Product

Cat #: 71210047

LymphoTrack^® IGH FR3 Assay – S5/PGM™

The LymphoTrack IGH FR3 Assay for the Ion S5/PGM represents a significant improvement over existing clonality assays using fragment analysis as they...

View Product

Cat #: 71210109

LymphoTrack^® IGH FR3 Assay Kit A – MiSeq^®

This LymphoTrack IGH Assay – MiSeq represents a significant improvement over existing clonality assays using fragment size analysis as it efficientl...

View Product

Cat #: 71210119

LymphoTrack^® IGH FR3 Assay Panel – MiSeq^®

This LymphoTrack IGH Assay – MiSeq represents a significant improvement over existing clonality assays using fragment size analysis as it efficientl...

View Product

Cat #: 71210059

LymphoTrack^® IGHV Leader Somatic Hypermutation Assay Kit A – MiSeq®

This LymphoTrack IGHV Leader Somatic Hypermutation Assay – MiSeq represents a significant improvement over existing clonality assays using fragmen...

View Product

Cat #: 71210069

LymphoTrack^® IGHV Leader Somatic Hypermutation Assay Panel – MiSeq®

This LymphoTrack IGHV Leader Somatic Hypermutation Assay – MiSeq represents a significant improvement over existing clonality assays using fragmen...

View Product

Cat #: 71220007

LymphoTrack^® IGK Assay – S5/PGM™

The human immunoglobulin kappa light chain (IGK) gene locus on chromosome 2 (2p11.2) includes many distinct Vϰ gene segments, grouped into seven Vϰ ...

View Product

Cat #: 71220009

LymphoTrack^® IGK Assay Kit A – MiSeq^®

The human immunoglobulin kappa light chain (IGK) gene locus on chromosome 2 (2p11.2) includes many distinct Vϰ gene segments, grouped into seven Vϰ ...

View Product

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021
Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

PRODUCTS & CLINICAL LAB SERVICES

Now Available

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

Now Available

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021 Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

PRODUCTS & CLINICAL LAB SERVICES

Now Available

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

Now Available

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021
Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing